152 related articles for article (PubMed ID: 35821355)
1. Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China.
Song Y; Li Y; Cheng H; Du X; Mi J; Le LV; Chen Z; Chan P; Sun J
Infect Dis Ther; 2022 Aug; 11(4):1427-1442. PubMed ID: 35821355
[TBL] [Abstract][Full Text] [Related]
2. What China can learn from Malaysia to achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review.
Sun J; Cheng H; Hassan MRA; Chan HK; Piedagnel JM
Lancet Reg Health West Pac; 2021 Nov; 16():100261. PubMed ID: 34590064
[No Abstract] [Full Text] [Related]
3. [Elimination of hepatitis C, our progress, challenges and hopes].
Rao HY; Li MY; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):809-811. PubMed ID: 33105921
[TBL] [Abstract][Full Text] [Related]
4. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
[TBL] [Abstract][Full Text] [Related]
5. How would China achieve WHO's target of eliminating HCV by 2030?
Li M; Zhuang H; Wei L
Expert Rev Anti Infect Ther; 2019 Oct; 17(10):763-773. PubMed ID: 31578079
[No Abstract] [Full Text] [Related]
6. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
7. China's efforts to shed its title of "Leader in liver disease".
Li X; Xu WF
Drug Discov Ther; 2007 Oct; 1(2):84-5. PubMed ID: 22504391
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis C elimination among drug users in China: challenges, strategies and experiences].
Wu T; Lin F; Wang J; Li H; Liu M; Zhang YR; Wang WW; Huang F
Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):1002-1006. PubMed ID: 36299198
[TBL] [Abstract][Full Text] [Related]
9. [Price analyses on direct-acting antiviral drugs of hepatitis C].
Duan CAX; Sui BY; Chen ZD; Zhao K
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1161-1164. PubMed ID: 33115205
[TBL] [Abstract][Full Text] [Related]
10. Expanding public health in China: an empirical analysis of healthcare inputs and outputs.
Deng F; Lv JH; Wang HL; Gao JM; Zhou ZL
Public Health; 2017 Jan; 142():73-84. PubMed ID: 28057203
[TBL] [Abstract][Full Text] [Related]
11. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME
BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275
[TBL] [Abstract][Full Text] [Related]
12. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
[TBL] [Abstract][Full Text] [Related]
13. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
[TBL] [Abstract][Full Text] [Related]
14. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.
Huang CF; Yu ML
Clin Mol Hepatol; 2020 Jul; 26(3):251-260. PubMed ID: 32188235
[TBL] [Abstract][Full Text] [Related]
15. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
16. Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin.
Zhang P; Guo R; Lian J; Zhi M; Lu C; Wu W; Wang L; Chan P; Chen Z; Sun J
Ann Glob Health; 2020 Apr; 86(1):36. PubMed ID: 32346522
[TBL] [Abstract][Full Text] [Related]
17. Experiences and Challenges of Implementing Universal Health Coverage With China's National Basic Public Health Service Program: Literature Review, Regression Analysis, and Insider Interviews.
Fang G; Yang D; Wang L; Wang Z; Liang Y; Yang J
JMIR Public Health Surveill; 2022 Jul; 8(7):e31289. PubMed ID: 35867386
[TBL] [Abstract][Full Text] [Related]
18. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
19. [Progress, challenges and countermeasures of global hepatitis C elimination].
Chen ZD
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):812-816. PubMed ID: 33105922
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
